Literature DB >> 12601638

Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone.

H Vierhapper1, P Nowotny, W Waldhäusl.   

Abstract

The effect of the thiazolidinedione, rosiglitazone (8 mg/d for 7 days), on the production rates of testosterone (T), dihydrotestosterone (DHT), and cortisol (F) was studied in healthy men (n = 10) using the stable isotope dilution technique and mass spectrometry. Treatment with rosiglitazone resulted in a decrease in the production rates of T from, basal, 318 +/- 62 microg/h to 272 +/- 72 microg/h (P <.05). Production rates of DHT fell from, basal, 21 +/- 6 microg/h to 17 +/- 5 microg/h (P <.05). Hence, the ratio calcuated from the production rates of T and DHT was unchanged (basal, 17 +/- 7; rosiglitazone, 17 +/- 3). Production rates of cortisol were unchanged (basal, 577 +/- 136 microg/h; rosiglitazone, 627 +/- 141 microg/h). These results suggest that a clinically relevant dose of at least one thiazolidindione, rosiglitazone, impedes the production of testosterone in man. Copyright 2003, Elsevier Science (USA). All rights reserved

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601638     DOI: 10.1053/meta.2003.50028

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

Review 1.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

2.  Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome.

Authors:  Heath J Antoine; Marita Pall; Belynda C Trader; Yii-Der I Chen; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2006-12-04       Impact factor: 7.329

3.  Testosterone and insulin resistance in the metabolic syndrome and T2DM in men.

Authors:  Preethi M Rao; Daniel M Kelly; T Hugh Jones
Journal:  Nat Rev Endocrinol       Date:  2013-06-25       Impact factor: 43.330

4.  Thiazolidinedione use and bone loss in older diabetic adults.

Authors:  Ann V Schwartz; Deborah E Sellmeyer; Eric Vittinghoff; Lisa Palermo; Beata Lecka-Czernik; Kenneth R Feingold; Elsa S Strotmeyer; Helaine E Resnick; Laura Carbone; Brock A Beamer; Seok Won Park; Nancy E Lane; Tamara B Harris; Steven R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2006-04-11       Impact factor: 5.958

5.  Glucose ingestion acutely lowers pulsatile LH and basal testosterone secretion in men.

Authors:  Ali Iranmanesh; Donna Lawson; Johannes D Veldhuis
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-17       Impact factor: 4.310

6.  The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes.

Authors:  Hong Li; Ran Cui; Haidong Cai; Guoting Wu; Zhongwei Lv; Chunjun Sheng; Xiaoyun Cheng; Fang Li; Yongchun Yu
Journal:  J Bone Miner Metab       Date:  2009-07-16       Impact factor: 2.626

7.  Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies.

Authors:  Janaína A Couto; Karina L A Saraiva; Cleiton D Barros; Daniel P Udrisar; Christina A Peixoto; Juliany S B César Vieira; Maria C Lima; Suely L Galdino; Ivan R Pitta; Maria I Wanderley
Journal:  Reprod Biol Endocrinol       Date:  2010-02-09       Impact factor: 5.211

8.  Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.

Authors:  Mojca Jensterle; Andrej Janez; Bojan Vrtovec; Helena Meden-Vrtovec; Marija Pfeifer; Janez Prezelj; Tomaz Kocjan
Journal:  Croat Med J       Date:  2007-12       Impact factor: 1.351

Review 9.  Are the adverse effects of glitazones linked to induced testosterone deficiency?

Authors:  M Carruthers; T R Trinick; E Jankowska; A M Traish
Journal:  Cardiovasc Diabetol       Date:  2008-10-15       Impact factor: 9.951

10.  Activation of PPARγ by Rosiglitazone does not negatively impact male sex steroid hormones in diabetic rats.

Authors:  Mahmoud Mansour; Elaine Coleman; John Dennis; Benson Akingbemi; Dean Schwartz; Tim Braden; Robert Judd; Eric Plaisance; Laura Ken Stewart; Edward Morrison
Journal:  PPAR Res       Date:  2009-06-11       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.